Analytical approaches for assessing aggregation of protein biopharmaceuticals

Research output: Contribution to journalArticleResearchpeer-review

11 Citations (Scopus)


Production of protein-based pharmaceuticals is a major issue in conventional pharmacology, biomedicine and nanomedicine. Being mostly obtained by genetic engineering, the quality and activity of protein drugs is a steady matter of concern. Although the physiology of the host recombinant cells, mostly mammalian and microbial, is progressively understood, the complexity of the cellular quality control systems escapes rational protein and process engineering, and recombinant proteins are often unstable, aggregate and/or do not reach the fully native conformation compatible with proper biological activity. In this review, we summarize the main biological aspects of protein folding and misfolding, mainly focusing in microbial cells, the newest insights in the biological control of protein quality and the main and analytical approaches that are suitable for the fast evaluation of the conformational quality and aggregation of recombinant drugs, even if showing apparent solubility. © 2011 Bentham Science Publishers.
Original languageEnglish
Pages (from-to)1530-1536
JournalCurrent Pharmaceutical Biotechnology
Issue number10
Publication statusPublished - 1 Jan 2011


  • Aggregation
  • Analytical procedures
  • Protein drugs
  • Recombinant proteins
  • Screening


Dive into the research topics of 'Analytical approaches for assessing aggregation of protein biopharmaceuticals'. Together they form a unique fingerprint.

Cite this